Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

This large real-world study confirms pembrolizumab's effectiveness and manageable safety profile in the adjuvant setting for intermediate-high and high-risk ccRCC. Further research is needed to refine patient selection strategies and evaluate long-term outcomes.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Immunotherapy
Published
2025-11-14
DOI
https://doi.org/10.1007/s00262-025-04230-w
Citations
1
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

Maria Teresa Bourlon, Ondřej Fiala, Zin Myint, Umut Akova et al.
1 citations
Cancer Immunology Immunotherapy
Renal cell carcinoma treatment
1.52
article

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

Maria Teresa Bourlon, Ondřej Fiala, Zin Myint, Umut Akova, Sebastiano Buti, Camillo Porta, Matteo Santoni, Thomas Büttner, Jakub Kucharz, Hatice Bölek, Luca Galli, Andrey Soares, Ahmet Yildirim, Veronica Mollica, Giandomenico Roviello, Enrique Grande, Vincenza Conteduca, Javier Molina‐Cerrillo, Mimma Rizzo, Jindřich Kopecký, Ray Manneh Kopp, Francesco Massari, Yüksel Ürün, Fernando Sabino Marques Monteiro, Anca Florina Zgura, Renate Pichler, Matteo Rosellini, Umberto Basso, Tomáš Büchler, Álvaro Pinto, Alessandro Rizzo, Mehmet Asim Bilen, Haoran Li, Timothy Schieber, Antonia Partl
article en
1 citations

Abstract

This large real-world study confirms pembrolizumab's effectiveness and manageable safety profile in the adjuvant setting for intermediate-high and high-risk ccRCC. Further research is needed to refine patient selection strategies and evaluate long-term outcomes.

Cancer Immunology ImmunotherapyVol. 74(12)
University of Foggia (IT), University of Parma (IT), Innsbruck Medical University (AT), Ankara University (TR), Emory University (US), Carol Davila University of Medicine and Pharmacy (RO), Universität Innsbruck (AT), Charles University (CZ), University Hospital Bonn (DE), Hospital Israelita Albert Einstein (BR), Hospital Universitario La Paz (ES), Markey Cancer Center (US), Westwood College (US), Popular University of Cesar (CO), Ospedali Riuniti di Foggia (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), The University of Kansas Cancer Center (US), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), University Hospital in Motol (CZ), Istituto Oncologico Veneto (IT), Azienda USL di Bologna (IT), Institutul Oncologic Bucuresti (RO), Istituto Tumori Bari (IT), University Hospital Hradec Králové (CZ), Hospital Sírio-Libanês (BR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), MD Anderson Cancer Center Madrid (ES), Hospital Universitario Ramón y Cajal (ES), Azienda Ospedaliera Universitaria Pisana (IT), Ospedale di Macerata, University of Florence (IT), University of Macerata (IT), University of Bari Aldo Moro (IT), University of Bologna (IT)
Openalex Percentile: Top 13%
Renal cell carcinoma treatment
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.